Drug Delivery: Facing Challenges
Innovative, non-invasive delivery includes improvement of patient acceptability and compliance, improvement in public safety, decrease of administration costs and a reduction of adverse effects. Enzyme degradation, acid degradation, hydrolysis and low permeability of intestinal epithelium in the GI tract surfaces make oral administration a non-viable delivery method. Proteins are administered parenterally as oral administration cause low bioavailability in the GI tract. It has become a challenge to achieve consistent and adequate bioavailability levels for oral administration.
Economic and financial barriers also stand in the way of implementing nano medicine. The limited availability of reimbursement by public and private health insurers for expensive new diagnostic tests has emerged as a major impediment to the deployment of personalized medicine. Nanoproducts encounter even greater hurdles because of their costs and complexity, cytotoxicity of nanoparticles are main concern of future research.
Advances in medical science, research and development (R&D) are changing the dynamics of the life science industry which includes pharmaceuticals and healthcare. The development of new drugs enhances the development of different drug delivery systems, which is further driven by innovation in technology, R&D and scientific advancements. Advances in understanding human diseases and medical treatments are opening new opportunities in the pharma industry. A better technology for drug administration or delivery is in demand now.